Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

Baartscheer, Antonius; A. Schumacher, Cees; C. I. Wüst, Rob; W.T. Fiolet, Jan; J.M. Stienen, Ger; Coronel, Ruben; J. Zuurbier, Coert

doi:10.1007/s00125-016-4134-x

Public

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

Published in Diabetologia • Oct 17, 2016

Authors:

Antonius Baartscheer

Cees A. Schumacher

Rob C. I. Wüst

Abstract

Empagliflozin (EMPA), an inhibitor of the renal sodium–glucose cotransporter (SGLT) 2, reduces the risk of cardiovascular death in patients with type 2 diabetes. The underlying mechanism of this effect is unknown. Elevated cardiac cytoplasmic Na+ ([Na+]c) and Ca2+ ([Ca2+]c) concentrations and decrea...

Subject

Empagliflozin

EMPA

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!